Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA REG OUTCOME trial
Atrial fibrillation (AF) is common in patients with diabetes and heart failure (HF) and increases the future risk of adverse cardiovascular (CV) outcomes. This analysis from the EMPA REG OUTCOME trial explores CV and renal outcomes in patients with vs. without AF at baseline and assesses the benefits of empagliflozin.
European journal of heart failure